Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

Blood

Volumn 127, Issue 9, 2016, Pages 1151-1162

  Paiva, Bruno ^a   Mateos, María Victoria ^b   Sanchez Abarca, Luis Ignacio ^b   Puig, Noemi ^b   Vidriales, María Belén ^b   López Corral, Lucía ^b   Corchete, Luis A ^b   Hernandez, Miguel T ^c   Bargay, Joan ^d   De Arriba, Felipe ^e   De La Rubia, Javier ^f   Teruel, Ana Isabel ^g   Giraldo, Pilar ^h   Rosiñol, Laura ⁱ   Prosper, Felipe ^a   Oriol, Albert ^j   Hernández, José ^k   Esteves, Graça ^l   Lahuerta, Juan José ^m   Bladé, Joan ⁱ   Perez Simon, Jose Antonio ⁿ   Miguel, Jesús F San ^a   Palomera, Luis ^o   Mariz, M ^p   Parreira, J ^q   De La Guía, A López ^r   Alegreamor, A ^s   Galiana, M Luz Martino ⁿ   Casasús, A I Teruel ^t   Zamudio, J L Guzmán ^u   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d Hospital Sont Llatzer   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g UNIVERSITY OF VALENCIA   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k HOSPITAL GENERAL DE SEGOVIA   (Spain)

^l HOSPITAL DE SANTA MARIA   (Portugal)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^p PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^q INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^r HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^s HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^t HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^u HOSPITAL DE JEREZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DEXAMETHASONE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; INTERLEUKIN 2; LENALIDOMIDE; T LYMPHOCYTE RECEPTOR DELTA CHAIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; THALIDOMIDE; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNE STATUS; IMMUNOMODULATION; LONGITUDINAL STUDY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SMOLDERING MULTIPLE MYELOMA; TREATMENT DURATION; UPREGULATION; AGED; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; RISK FACTOR; T LYMPHOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL PROLIFERATION; DEMOGRAPHY; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK FACTORS; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84960425700     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-662320     Document Type: Article

References (55)

1. López-Corral L, Mateos MV, Corchete LA, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica. 2012;97(9):1439-1443.
2. López-Corral L, Gutiérrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17(7):1692-1700.
3. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28(2):384-390.
4. López-Corral L, Sarasquete ME, Beà S, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012;26(12):2521-2529.
5. Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del (17p), t (4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325-4332.
6. Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738-1744.
7. Zhao S, Choi M, Heuck C, et al. Serial exome analysis of disease progression in premalignant gammopathies. Leukemia. 2014;28(7):1548-1552.
8. Paiva B, Gutiérrez NC, Chen X, et al; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012;26(8):1862-1869.
9. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138(5):563-579.
10. Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015;5:e306.
11. Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-2592.
12. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369-380.
13. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8 (1) CD57 (1) CD28 (-) compartment. Blood. 2001;98(9):2817-2827.
14. Brown RD, Pope B, Yuen E, Gibson J, Joshua DE. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma. 1998;31(3-4):379-384.
15. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286-2294.
16. Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29(10):2110-2113.
17. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
18. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590.
19. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438-447.
20. Mateos M, Hernandez MT, Giraldo P, et al. Long term follow-up on the tretament [sic] of high risk smoldering myeloma with lenalidomide plus low dose dex (rd) (phase III spanish trial): persistent benefit in overall survival [abstract]. Blood. 2014;124(21). Abstract 3465.
21. Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of lenalidomide extinguished by co-administration of Dexamethasone? OncoImmunology. 2012;1(3):372-374.
22. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NKcell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-1613.
23. Carter CR, Feyler S, Smalle N, et al. Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients. Blood. 2011;118(24):6465-6466, author reply 6466-6468.
24. Busch A, Zeh D, Janzen V, et al. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol. 2014;177(2):439-453.
25. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-167.
26. Rajkumar SV, Kyle RA. Haematological cancer: Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol. 2013;10(10):554-555.
27. Kalina T, Flores-Montero J, van der Velden VH, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
28. Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591-3598.
29. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
30. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123(1):78-85.
31. Costello RT, Boehrer A, Sanchez C, et al. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology. 2013;139(3):338-341.
32. Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 2008;112(7):2878-2885.
33. Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003;197(12):1667-1676.
34. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003;198(11):1753-1757.
35. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006;20(4):732-733.
36. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA. 2008;105(4):1285-1290.
37. Martín-Ayuso M, Almeida J, Pérez-Andrés M, et al. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist. 2008;13(1):82-92.
38. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010;116(18):3554-3563.
39. Ogawara H, Handa H, Yamazaki T, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res. 2005;29(2):135-140.
40. Pérez-Andres M, Almeida J, Martin-Ayuso M, et al; Spanish Network on Multiple Myeloma; Spanish Network of Cancer Research Centers. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCRVbeta repertoire. Cancer. 2006;106(6):1296-1305.
41. Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79-86.
42. Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385-5392.
43. Bryant C, Suen H, Brown R, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148.
44. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785-789.
45. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106(3):546-552.
46. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077.
47. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305.
48. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
49. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50-60.
50. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108(2):618-621.
51. Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042-4051.
52. Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma. 2012;53(7):1406-1408.
53. Scott GB, Carter C, Parrish C, Wood PM, Cook G. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Cell Immunol. 2015;297(1):1-9.
54. Nagar M, Jacob-Hirsch J, Vernitsky H, et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA-regulatory T cells that modulates their suppressive function. J Immunol. 2010;184(7):3570-3581.
55. San Miguel JF, Paiva B, Lasarte JJ. Engineering antimyeloma responses using affinity-enhanced TCRengineered T cells. Cancer Cell. 2015;28(3):281-283.